RxDoctor Payments Data

Vinay Sunku, MD

Nephrology · Lancaster, CANPI 1326039405

Payments from drug & device makers

$7,304in general payments, 2019–2025

Across 35 payments — averaging $208.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Vertex$2K
  • Novartis$253
  • Akebia Therapeutics Inc$166
  • Bayer$138
  • Amgen$38
  • plus $154 from 7 others

What the payments were for

  • Speaking & faculty fees$22526%
  • Food & beverage$60271%
  • Education$253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,304 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$357,651
Medicare patients
279
Services billed
2,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide25$94,219
JardianceEmpagliflozin70$52,926
LokelmaSodium Zirconium Cyclosilicate33$40,318
AuryxiaFerric Citrate20$27,531
FarxigaDapagliflozin Propanediol20$18,942
KerendiaFinerenone11$15,165
ProsolParenteral Amino Acid 20% No.170$14,549
Sevelamer Carbonate61$10,941
Calcium Acetate43$6,475
Nifedipine ErNifedipine32$1,154
Metoprolol Succinate47$798
Amlodipine Besylate163$634
Furosemide80$563
Labetalol Hcl18$540
Terazosin Hcl31$478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$16$94,21925 claims
AstraZenecaLokelma, Farxiga$4,150$59,26053 claims
Akebia Therapeutics IncAuryxia$166$27,53120 claims
BayerKerendia$138$15,16511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.

Other nephrology in Lancaster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →